Ionis Pharmaceuticals Stock Price, News & Analysis (NASDAQ:IONS)

$50.05 +0.27 (+0.54 %)
(As of 02/18/2018 04:00 PM ET)
Previous Close$50.05
Today's Range$49.68 - $50.90
52-Week Range$37.26 - $65.51
Volume497,146 shs
Average Volume1.00 million shs
Market Capitalization$6.25 billion
P/E Ratio357.50
Dividend YieldN/A
Beta2.53

About Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals logoIonis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.

Receive IONS News and Ratings via Email

Sign-up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:IONS
CUSIP46433010
Phone+1-760-9319200

Debt

Debt-to-Equity Ratio1.50%
Current Ratio6.25%
Quick Ratio6.21%

Price-To-Earnings

Trailing P/E Ratio357.5
Forward P/E Ratio-357.50
P/E GrowthN/A

Sales & Book Value

Annual Sales$346.62 million
Price / Sales18.02
Cash FlowN/A
Price / CashN/A
Book Value$0.82 per share
Price / Book61.04

Profitability

Trailing EPS$0.14
Net Income$-86,550,000.00
Net Margins3.46%
Return on Equity7.50%
Return on Assets1.58%

Miscellaneous

Employees435
Outstanding Shares124,800,000

Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced its quarterly earnings data on Tuesday, August, 9th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.52) by $0.05. The firm earned $38.50 million during the quarter, compared to the consensus estimate of $38.52 million. Ionis Pharmaceuticals had a return on equity of 7.50% and a net margin of 3.46%. The company's revenue for the quarter was down 68.0% compared to the same quarter last year. View Ionis Pharmaceuticals' Earnings History.

When will Ionis Pharmaceuticals make its next earnings announcement?

Ionis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for Ionis Pharmaceuticals.

Where is Ionis Pharmaceuticals' stock going? Where will Ionis Pharmaceuticals' stock price be in 2018?

13 brokers have issued 12 month price objectives for Ionis Pharmaceuticals' stock. Their forecasts range from $18.00 to $65.00. On average, they expect Ionis Pharmaceuticals' stock price to reach $50.92 in the next year. View Analyst Ratings for Ionis Pharmaceuticals.

What are Wall Street analysts saying about Ionis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Ionis Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California. " (2/10/2018)
  • 2. BMO Capital Markets analysts commented, " We maintain our Outperform rating, but decrease our price target to $59 from $63, following Phase III volanesorsen FCS data that showed strong efficacy, but higher frequency of platelet monitoring to maintain treatment. While we believe volanesorsen will be approved, biweekly monitoring and injection site reactions (ISRs) could limit patient adherence to therapy, leading us to decrease our compliance/ persistence rate to 75% from 85%. Our market share assumptions remain unchanged, given the disease burden and limited treatment options. We estimate Volanesorsen WW peak sales of $820 million." (3/7/2017)

Who are some of Ionis Pharmaceuticals' key competitors?

Who are Ionis Pharmaceuticals' key executives?

Ionis Pharmaceuticals' management team includes the folowing people:

  • Stanley T. Crooke M.D. Ph.D., Chairman of the Board, President, Chief Executive Officer (Age 72)
  • Elizabeth L. Hougen, Chief Financial Officer, Senior Vice President - Finance (Age 55)
  • B. Lynne Parshall J.D., Chief Operating Officer, Corporate Secretary, Director (Age 63)
  • Patrick R. O'Neil Esq., Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary (Age 43)
  • C. Frank Frank Bennett Ph.D., Senior Vice President - Antisense Research (Age 60)
  • Richard S. Geary Ph.D., Senior Vice President - Development (Age 59)
  • Brett P. Monia Ph.D., Senior Vice President - Drug Discovery and Corporate Development (Age 55)
  • Sarah Boyce, Chief Business Officer (Age 45)
  • Spencer R. Berthelsen M.D., Independent Director (Age 64)
  • Breaux B. Castleman, Independent Director (Age 76)

Who owns Ionis Pharmaceuticals stock?

Ionis Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Clearbridge Investments LLC (8.80%), BlackRock Inc. (5.59%), OppenheimerFunds Inc. (2.16%), Pinnacle Associates Ltd. (1.03%), American Century Companies Inc. (0.95%) and Wells Fargo & Company MN (0.88%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Ionis Pharmaceuticals Inc, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.

Who sold Ionis Pharmaceuticals stock? Who is selling Ionis Pharmaceuticals stock?

Ionis Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Clearbridge Investments LLC, Gotham Asset Management LLC, Franklin Resources Inc., Altrinsic Global Advisors LLC, Pinnacle Associates Ltd., Wells Fargo & Company MN and First Trust Advisors LP. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.

Who bought Ionis Pharmaceuticals stock? Who is buying Ionis Pharmaceuticals stock?

Ionis Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Two Sigma Investments LP, Tocqueville Asset Management L.P., Tekla Capital Management LLC, ARK Investment Management LLC, Two Sigma Advisers LP, AXA and Allianz Asset Management GmbH. View Insider Buying and Selling for Ionis Pharmaceuticals.

How do I buy Ionis Pharmaceuticals stock?

Shares of Ionis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ionis Pharmaceuticals' stock price today?

One share of Ionis Pharmaceuticals stock can currently be purchased for approximately $50.05.

How big of a company is Ionis Pharmaceuticals?

Ionis Pharmaceuticals has a market capitalization of $6.25 billion and generates $346.62 million in revenue each year. The company earns $-86,550,000.00 in net income (profit) each year or $0.14 on an earnings per share basis. Ionis Pharmaceuticals employs 435 workers across the globe.

How can I contact Ionis Pharmaceuticals?

Ionis Pharmaceuticals' mailing address is 2855 Gazelle Ct, CARLSBAD, CA 92010-6670, United States. The company can be reached via phone at +1-760-9319200.


MarketBeat Community Rating for Ionis Pharmaceuticals (IONS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  399 (Vote Outperform)
Underperform Votes:  404 (Vote Underperform)
Total Votes:  803
MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ionis Pharmaceuticals (NASDAQ:IONS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.312.312.292.36
Ratings Breakdown: 2 Sell Rating(s)
5 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
5 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
5 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $50.92$50.92$50.38$49.00
Price Target Upside: 6.90% downside6.90% downside7.87% downside3.35% upside

Ionis Pharmaceuticals (NASDAQ:IONS) Consensus Price Target History

Price Target History for Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals (NASDAQ:IONS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/8/2017BMO Capital MarketsBoost Price TargetOutperform$64.00 -> $65.00N/AView Rating Details
11/8/2017Morgan StanleyBoost Price TargetEqual Weight$45.00 -> $49.00N/AView Rating Details
10/17/2017Needham & Company LLCReiterated RatingBuy$64.00N/AView Rating Details
10/13/2017Stifel NicolausReiterated RatingHold$50.00N/AView Rating Details
10/6/2017Goldman Sachs GroupReiterated RatingSell -> Sell$30.00N/AView Rating Details
9/21/2017BarclaysLower Price TargetEqual Weight$55.00 -> $52.00LowView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$65.00LowView Rating Details
8/14/2017LaidlawReiterated RatingBuy$65.00LowView Rating Details
8/10/2017Jefferies GroupReiterated RatingUnderperform$17.00 -> $18.00HighView Rating Details
7/27/2017Sanford C. BernsteinInitiated CoverageMarket Perform$57.00HighView Rating Details
5/22/2017CowenReiterated RatingMarket PerformLowView Rating Details
5/17/2017Leerink SwannReiterated RatingOutperform$47.00 -> $45.00MediumView Rating Details
5/10/2017Piper Jaffray CompaniesSet Price TargetBuy$66.00 -> $51.00LowView Rating Details
1/5/2017Janney Montgomery ScottSet Price TargetHold$44.00N/AView Rating Details
11/10/2016JPMorgan Chase & Co.Reiterated RatingHold$35.00N/AView Rating Details
9/11/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
(Data available from 2/18/2016 forward)

Earnings

Ionis Pharmaceuticals (NASDAQ:IONS) Earnings History and Estimates Chart

Earnings by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals (NASDAQ IONS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018($0.06)N/AView Earnings Details
8/8/2017Q2 2017($0.06)($0.09)$93.29 million$104.15 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.10)$0.03$86.03 million$110.30 millionViewListenView Earnings Details
2/28/2017Q416($0.20)$0.33$97.47 million$160.30 millionViewListenView Earnings Details
11/9/2016Q316$0.07$0.06$114.65 million$110.90 millionViewListenView Earnings Details
8/9/2016Q216($0.52)($0.47)$38.52 million$38.50 millionViewN/AView Earnings Details
5/4/2016Q116($0.50)($0.52)$36.21 million$36.90 millionViewN/AView Earnings Details
2/25/2016Q415($0.47)($0.59)$49.32 million$51.60 millionViewListenView Earnings Details
11/9/2015Q315($0.31)($0.30)$52.93 million$49.10 millionViewN/AView Earnings Details
8/4/2015Q215$0.29$0.29$114.93 million$120.40 millionViewN/AView Earnings Details
5/5/2015Q115($0.19)($0.14)$52.74 million$62.60 millionViewN/AView Earnings Details
2/27/2015Q414$0.12$0.25$74.58 million$84.90 millionViewN/AView Earnings Details
11/7/2014Q314($0.20)($0.23)$45.79 million$44.10 millionViewN/AView Earnings Details
8/4/2014Q214($0.12)($0.10)$45.60 million$57.08 millionViewN/AView Earnings Details
5/6/2014Q114($0.23)($0.27)$35.12 million$28.20 millionViewN/AView Earnings Details
2/28/2014Q413($0.17)($0.21)$34.20 million$42.25 millionViewN/AView Earnings Details
11/5/2013Q313($0.27)($0.21)$19.82 million$23.60 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.21)($0.09)$26.76 million$38.10 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.02)($0.02)$45.24 million$43.36 millionViewListenView Earnings Details
2/28/2013Q4 2012($0.23)($0.03)$15.78 million$19.90 millionViewListenView Earnings Details
11/6/2012Q312($0.26)($0.37)$23.11 million$11.60 millionViewN/AView Earnings Details
8/6/2012($0.08)($0.01)ViewN/AView Earnings Details
5/8/2012($0.28)($0.24)ViewN/AView Earnings Details
2/29/2012($0.13)($0.20)ViewN/AView Earnings Details
11/7/2011($0.20)($0.27)ViewN/AView Earnings Details
8/4/2011($0.22)($0.18)ViewN/AView Earnings Details
5/5/2011($0.19)($0.20)ViewN/AView Earnings Details
2/28/2011($0.22)($0.14)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.20)($0.13)ViewN/AView Earnings Details
8/9/2010Q2 2010($0.15)($0.25)ViewN/AView Earnings Details
5/6/2010Q1 2010($0.17)($0.10)ViewN/AView Earnings Details
3/1/2010Q4 2009($0.11)($0.16)ViewN/AView Earnings Details
11/5/2009Q3 2009($0.05)($0.07)ViewN/AView Earnings Details
8/6/2009Q2 2009($0.01)($0.03)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.04)$0.03ViewN/AView Earnings Details
2/25/2009Q4 2008($0.03)($0.06)ViewN/AView Earnings Details
11/10/2008Q3 2008($0.05)$0.03ViewN/AView Earnings Details
8/7/2008Q2 2008($0.05)($0.02)ViewN/AView Earnings Details
5/12/2008Q1 2008($0.11)($0.05)ViewN/AView Earnings Details
3/13/2008Q4 2007($0.08)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Ionis Pharmaceuticals (NASDAQ:IONS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.56)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.28)($0.04)($0.16)
Q2 20182($0.29)($0.03)($0.16)
Q3 20182($0.27)$0.00($0.14)
Q4 20182($0.25)$0.05($0.10)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Ionis Pharmaceuticals (NASDAQ:IONS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Ionis Pharmaceuticals (NASDAQ IONS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.13%
Institutional Ownership Percentage: 91.40%
Insider Trades by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)
Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals (NASDAQ IONS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/15/2018Joseph Klein IIIDirectorSell3,000$48.99$146,970.0011,339View SEC Filing  
2/1/2018C Frank BennettSVPSell12,500$52.50$656,250.00View SEC Filing  
1/30/2018Joseph Klein IIIDirectorSell3,000$52.86$158,580.00View SEC Filing  
1/29/2018Patrick R O'neilSVPSell355$55.00$19,525.0014,507View SEC Filing  
1/29/2018Stanley T CrookeChairmanSell11,000$54.12$595,320.00View SEC Filing  
1/25/2018Patrick R O'neilSVPSell645$55.00$35,475.0015,097View SEC Filing  
1/16/2018B Lynne ParshallDirectorSell5,986$51.76$309,835.3644,166View SEC Filing  
1/16/2018Brett P MoniaCOOSell2,821$51.76$146,014.9618,604View SEC Filing  
1/16/2018C Frank BennettSVPSell2,696$51.76$139,544.9621,810View SEC Filing  
1/16/2018Elizabeth L HougenCFOSell2,724$51.76$140,994.2417,224View SEC Filing  
1/16/2018Sarah BoyceInsiderSell2,196$51.76$113,664.9611,127View SEC Filing  
1/15/2018Stanley T CrookeChairmanSell16,549$51.76$856,576.2467,626View SEC Filing  
1/8/2018Stanley T CrookeChairmanSell11,000$52.01$572,110.0048,014View SEC Filing  
1/3/2018Stanley T CrookeChairmanSell22,000$50.01$1,100,220.0058,014View SEC Filing  
1/2/2018Brett P MoniaSVPSell163$50.00$8,150.0011,782View SEC Filing  
12/29/2017Joseph Klein IIIDirectorSell3,000$50.56$151,680.00View SEC Filing  
12/29/2017Joseph Klein IIIDirectorSell3,000$50.56$151,680.0012,939View SEC Filing  
12/15/2017Elizabeth L HougenSVPSell5,000$52.55$262,750.0015,392View SEC Filing  
12/15/2017Joseph Klein IIIDirectorSell3,000$51.69$155,070.0012,939View SEC Filing  
12/4/2017Elizabeth L HougenSVPSell4,000$57.00$228,000.0014,392View SEC Filing  
12/1/2017Patrick R O'neilSVPSell1,000$55.50$55,500.0011,433View SEC Filing  
11/30/2017Joseph Klein IIIDirectorSell3,000$53.55$160,650.0012,939View SEC Filing  
11/29/2017Elizabeth L HougenSVPSell6,000$53.02$318,120.0016,392View SEC Filing  
11/16/2017Elizabeth L HougenSVPSell7,000$54.35$380,450.0017,392View SEC Filing  
11/15/2017Joseph Klein IIIDirectorSell2,250$53.56$120,510.009,377View SEC Filing  
11/13/2017Joseph Klein IIIDirectorSell3,000$55.39$166,170.007,127View SEC Filing  
11/1/2017Patrick R O'neilSVPSell1,000$58.35$58,350.0011,433View SEC Filing  
10/18/2017B Lynne ParshallCOOSell16,118$65.00$1,047,670.0033,526View SEC Filing  
10/18/2017C Frank BennettSVPSell12,250$65.00$796,250.0027,291View SEC Filing  
10/13/2017Richard S GearySVPSell8,268$60.00$496,080.00View SEC Filing  
10/13/2017Stanley T CrookeChairmanSell16,500$59.46$981,090.00View SEC Filing  
10/5/2017Patrick R O'neilSVPSell1,000$55.00$55,000.00View SEC Filing  
10/4/2017Stanley T CrookeChairmanSell27,500$52.89$1,454,475.00View SEC Filing  
10/2/2017Stanley T CrookeCEOSell15,000$52.00$780,000.0043,014View SEC Filing  
9/6/2017Patrick R O'neilSVPSell1,000$55.00$55,000.0010,633View SEC Filing  
7/24/2017C Frank BennettSVPSell10,000$59.29$592,900.0025,041View SEC Filing  
7/20/2017Stanley T CrookeChairmanSell11,000$55.35$608,850.0048,014View SEC Filing  
7/19/2017Ionis Pharmaceuticals IncMajor ShareholderBuy3,125,000$8.00$25,000,000.0028,884,540View SEC Filing  
7/17/2017Stanley T CrookeChairmanSell16,500$52.45$865,425.0053,014View SEC Filing  
7/3/2017Brett P MoniaSVPSell309$51.35$15,867.1511,935View SEC Filing  
7/3/2017Stanley T CrookeChairmanSell16,500$52.10$859,650.0051,476View SEC Filing  
6/1/2017Patrick R O'neilSVPSell70$48.00$3,360.0010,369View SEC Filing  
5/1/2017Patrick R O'neilSVPSell650$48.75$31,687.5010,299View SEC Filing  
4/25/2017Stanley T CrookeChairmanSell16,500$47.81$788,865.0053,014View SEC Filing  
4/24/2017Patrick R O'neilSVPSell500$45.00$22,500.0010,523View SEC Filing  
4/19/2017Stanley T CrookeChairmanSell5,500$43.25$237,875.0043,014View SEC Filing  
4/13/2017Stanley T CrookeChairmanSell22,000$40.69$895,180.0048,014View SEC Filing  
4/12/2017Patrick R O'neilSVPSell1,000$40.07$40,070.0010,449View SEC Filing  
3/3/2017C Frank BennettSVPSell5,000$55.00$275,000.0019,788View SEC Filing  
3/1/2017B Lynne ParshallCOOSell4,625$49.26$227,827.5030,276View SEC Filing  
3/1/2017Patrick R O'neilSVPSell1,500$49.29$73,935.0012,949View SEC Filing  
2/6/2017Patrick R O'neilSVPSell1,500$46.17$69,255.0012,449View SEC Filing  
1/17/2017B Lynne ParshallCOOSell7,246$46.29$335,417.3419,459View SEC Filing  
1/17/2017Brett P MoniaSVPSell2,502$46.29$115,817.589,287View SEC Filing  
1/17/2017Elizabeth L HougenCFOSell2,273$46.29$105,217.177,059View SEC Filing  
1/17/2017Sarah BoyceInsiderSell1,361$46.29$63,000.695,318View SEC Filing  
1/17/2017Stanley T CrookeCEOSell15,382$46.29$712,032.7830,576View SEC Filing  
1/10/2017Stanley T CrookeChairmanSell13,200$49.25$650,100.0037,029View SEC Filing  
1/4/2017Stanley T CrookeChairmanSell18,700$48.89$914,243.0030,029View SEC Filing  
1/3/2017Brett P MoniaSVPSell309$48.60$15,017.408,181View SEC Filing  
12/20/2016Brett P MoniaSVPSell130$52.48$6,822.407,872View SEC Filing  
12/15/2016B Lynne ParshallCOOSell4,000$50.00$200,000.0016,693View SEC Filing  
12/5/2016Elizabeth L HougenCFOSell2,500$46.05$115,125.009,048View SEC Filing  
12/5/2016Patrick R O'neilSVPSell350$45.00$15,750.009,876View SEC Filing  
12/1/2016B Lynne ParshallCOOSell12,500$42.23$527,875.0023,693View SEC Filing  
11/14/2016Patrick R O'neilSVPSell1,000$45.00$45,000.009,720View SEC Filing  
11/11/2016Elizabeth L HougenSVPSell5,000$39.75$198,750.009,048View SEC Filing  
11/7/2016C Frank BennettSVPSell5,000$34.00$170,000.0015,803View SEC Filing  
10/5/2016Stanley T CrookeChairmanSell11,000$36.61$402,710.0035,029View SEC Filing  
9/27/2016Stanley T CrookeChairmanSell22,000$36.02$792,440.0045,029View SEC Filing  
9/21/2016Stanley T CrookeChairmanSell22,000$35.50$781,000.0045,029View SEC Filing  
9/1/2016B Lynne ParshallCOOSell12,500$29.88$373,500.0025,558View SEC Filing  
5/31/2016Frederick T MutoDirectorSell12,500$22.31$278,875.0015,043View SEC Filing  
4/6/2016Patrick R O'neilSVPSell1,000$45.00$45,000.0010,124View SEC Filing  
4/6/2016Stanley T CrookeCEOSell11,000$46.13$507,430.0030,029View SEC Filing  
3/31/2016Stanley T CrookeCEOSell11,000$40.74$448,140.0030,029View SEC Filing  
3/23/2016Patrick R O'neilSVPSell1,000$45.40$45,400.0010,124View SEC Filing  
1/19/2016B Lynne ParshallCOOSell5,192$41.46$215,260.3216,290View SEC Filing  
1/19/2016C Frank BennettSVPSell2,110$41.46$87,480.6010,590View SEC Filing  
1/19/2016Elizabeth L. HougenCFOSell1,899$41.46$78,732.546,331View SEC Filing  
1/19/2016Sarah BoyceinsiderSell872$41.46$36,153.121,735View SEC Filing  
1/19/2016Stanley T. CrookeCEOSell13,401$41.46$555,605.4625,029View SEC Filing  
1/5/2016Stanley T. CrookeCEOSell5,500$62.10$341,550.0014,642View SEC Filing  
1/4/2016B Lynne ParshallCOOSell809$61.05$49,389.458,215View SEC Filing  
1/4/2016Brett P. MoniaSVPSell127$61.00$7,747.004,358View SEC Filing  
1/4/2016Stanley T. CrookeCEOSell11,000$61.05$671,550.0014,642View SEC Filing  
12/16/2015C Frank BennettSVPSell7,909$57.41$454,055.697,316View SEC Filing  
12/1/2015Patrick R. O'neilSVPSell1,000$61.50$61,500.006,259View SEC Filing  
11/11/2015Joseph Klein IIIDirectorSell6,875$64.18$441,237.505,543View SEC Filing  
11/10/2015C Frank BennettSVPSell5,000$64.00$320,000.007,316View SEC Filing  
11/6/2015C Frank BennettSVPSell5,000$56.00$280,000.007,316View SEC Filing  
11/3/2015Patrick R. O'neilSVPSell1,000$51.95$51,950.006,259View SEC Filing  
10/23/2015Stanley T. CrookeCEOSell44,000$43.85$1,929,400.0014,642View SEC Filing  
10/2/2015B Lynne ParshallCOOSell12,436$40.75$506,767.008,143View SEC Filing  
7/6/2015B Lynne ParshallCOOSell6,218$57.01$354,488.18View SEC Filing  
7/6/2015Stanley T CrookeCEOSell5,000$57.01$285,050.00View SEC Filing  
7/1/2015B Lynne ParshallCOOSell6,218$57.56$357,908.08View SEC Filing  
7/1/2015Stanley T CrookeCEOSell6,175$57.56$355,433.00View SEC Filing  
6/8/2015Brett P MoniaSVPSell7,600$66.22$503,272.00View SEC Filing  
4/7/2015B Lynne ParshallCOOSell5,565$63.07$350,984.55View SEC Filing  
4/7/2015Stanley T CrookeCEOSell22,377$63.07$1,411,317.39View SEC Filing  
3/24/2015C Frank BennettSVPSell15,000$70.61$1,059,150.00View SEC Filing  
3/19/2015Elizabeth L HougenCFOSell10,000$73.33$733,300.00View SEC Filing  
3/19/2015Patrick R O'neilSVPSell30,525$74.85$2,284,796.25View SEC Filing  
3/2/2015Joseph H WenderDirectorSell7,000$65.97$461,790.00View SEC Filing  
1/27/2015Stanley T CrookeCEOSell11,000$72.93$802,230.00View SEC Filing  
1/16/2015B Lynne ParshallCOOSell4,093$67.96$278,160.28View SEC Filing  
1/16/2015Elizabeth L HougenCFOSell1,291$67.96$87,736.36View SEC Filing  
1/16/2015Richard S GearySVPSell1,543$67.96$104,862.28View SEC Filing  
1/16/2015Stanley T CrookeCEOSell9,054$67.96$615,309.84View SEC Filing  
1/9/2015Stanley T CrookeCEOSell11,000$73.57$809,270.00View SEC Filing  
1/7/2015Stanley T CrookeCEOSell22,000$67.04$1,474,880.00View SEC Filing  
1/2/2015B Lynne ParshallCOOSell11,200$62.12$695,744.00View SEC Filing  
1/2/2015Patrick R O'neilSVPSell1,500$62.12$93,180.00View SEC Filing  
12/1/2014Patrick R O'neilSVPSell1,500$51.21$76,815.00View SEC Filing  
11/3/2014Patrick R O'neilSVPSell1,500$46.17$69,255.00View SEC Filing  
10/30/2014B Lynne ParshallCOOSell11,071$45.12$499,523.52View SEC Filing  
10/23/2014Stanley T CrookeCEOSell14,600$42.22$616,412.00View SEC Filing  
10/3/2014Stanley T CrookeCEOSell36,000$38.52$1,386,720.00View SEC Filing  
10/1/2014Patrick R O'neilSVPSell1,500$38.04$57,060.00View SEC Filing  
10/1/2014Stanley T CrookeCEOSell20,000$37.91$758,200.00View SEC Filing  
8/27/2014C Frank BennettSVPSell5,000$40.53$202,650.00View SEC Filing  
8/13/2014Stanley T CrookeCEOSell15,500$35.45$549,475.00View SEC Filing  
8/12/2014Patrick R O'neilSVPSell1,500$35.00$52,500.00View SEC Filing  
8/1/2014Stanley T CrookeCEOSell16,000$30.53$488,480.00View SEC Filing  
7/31/2014Brett P MoniaSVPSell79$31.50$2,488.50View SEC Filing  
7/1/2014Patrick R O'neilSVPSell1,500$35.33$52,995.00View SEC Filing  
7/1/2014Stanley T CrookeCEOSell17,500$35.57$622,475.00View SEC Filing  
6/23/2014C Frank BennettSVPSell11,200$36.78$411,936.00View SEC Filing  
6/19/2014Stanley T CrookeCEOSell11,000$35.10$386,100.00View SEC Filing  
6/10/2014Stanley T CrookeCEOSell11,000$33.46$368,060.00View SEC Filing  
6/2/2014Frederick T MutoDirectorSell10,000$28.59$285,900.00View SEC Filing  
4/2/2014Stanley CrookeCEOSell8,800$43.65$384,120.006,941View SEC Filing  
1/30/2014B Lynne ParshallCOOSell89,510$49.49$4,429,849.904,022View SEC Filing  
1/24/2014Joseph Klein IIIDirectorSell10,313$48.66$501,830.582,313View SEC Filing  
1/22/2014Joseph WenderDirectorSell10,000$50.98$509,800.0031,135View SEC Filing  
1/22/2014Richard GearySVPSell22,200$50.05$1,111,110.004,955View SEC Filing  
1/16/2014B Lynne ParshallCOOSell1,641$47.08$77,258.284,022View SEC Filing  
1/16/2014Stanley CrookeCEOSell3,527$47.08$166,051.166,941View SEC Filing  
1/8/2014Richard GearySVPSell15,000$40.45$606,750.003,610View SEC Filing  
1/8/2014Stanley CrookeCEOSell12,500$40.05$500,625.001,661View SEC Filing  
1/2/2014Stanley CrookeCEOSell31,500$39.35$1,239,525.001,661View SEC Filing  
12/26/2013B Lynne ParshallCOOSell37,811$40.91$1,546,848.01956View SEC Filing  
12/24/2013B Lynne ParshallCOOSell70,000$41.49$2,904,300.00956View SEC Filing  
12/20/2013Joseph WenderDirectorSell19,731$39.58$780,952.9841,135View SEC Filing  
12/5/2013C Frank BennettSVPSell10,000$39.92$399,200.002,866View SEC Filing  
11/26/2013Joseph WenderDirectorSell10,000$36.63$366,300.0045,866View SEC Filing  
9/20/2013B Lynne ParshallCOOSell90,000$35.43$3,188,700.00956View SEC Filing  
9/20/2013Brett MoniaSVPSell68,281$34.21$2,335,893.01769View SEC Filing  
9/20/2013Stanley CrookeCEOSell58,740$35.19$2,067,060.601,661View SEC Filing  
9/19/2013C Frank BennettSVPSell10,000$35.02$350,200.002,866View SEC Filing  
9/11/2013B Lynne ParshallCOOSell63,505$31.04$1,971,195.20View SEC Filing  
9/9/2013C Frank BennettSVPSell10,000$30.23$302,300.00View SEC Filing  
9/4/2013Patrick R O'neilSVPSell2,500$27.09$67,725.00View SEC Filing  
8/26/2013Brett MoniaSVPSell2,909$25.58$74,412.22769View SEC Filing  
8/9/2013Joseph Klein IIIDirectorSell18,750$28.22$529,125.008,313View SEC Filing  
7/23/2013Stanley T CrookeCOOSell11,500$30.00$345,000.00View SEC Filing  
7/22/2013Stanley T CrookeCEOSell62,200$30.50$1,897,100.00View SEC Filing  
7/17/2013Stanley T CrookeCEOSell49,300$33.12$1,632,816.00View SEC Filing  
7/12/2013Stanley T CrookeCEOSell90,000$31.75$2,857,500.00View SEC Filing  
7/11/2013Richard S GearySVPSell9,000$31.90$287,100.00View SEC Filing  
7/9/2013Richard S GearySVPSell66,163$30.03$1,986,874.89View SEC Filing  
7/9/2013Stanley T CrookeCEOSell109,172$26.69$2,913,800.68View SEC Filing  
7/3/2013Richard S GearySVPSell5,000$29.02$145,100.00View SEC Filing  
7/1/2013Stanley T CrookeCEOSell50,683$27.65$1,401,384.95View SEC Filing  
6/26/2013Stanley T CrookeCEOSell90,000$26.73$2,405,700.00View SEC Filing  
6/25/2013Richard S GearySVPSell47,049$26.20$1,232,683.80View SEC Filing  
6/20/2013Joseph H WenderDirectorSell5,447$20.93$114,005.71View SEC Filing  
6/11/2013Brett P MoniaSVPSell9,375$23.76$222,750.00View SEC Filing  
5/30/2013Frederick T MutoDirectorSell10,000$21.96$219,600.00View SEC Filing  
1/16/2013Stanley T CrookeCEOSell1,460$14.00$20,440.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ionis Pharmaceuticals (NASDAQ IONS) News Headlines

Source:
DateHeadline
Ionis Pharmaceuticals Inc (IONS) Director Sells $146,970.00 in StockIonis Pharmaceuticals Inc (IONS) Director Sells $146,970.00 in Stock
www.americanbankingnews.com - February 16 at 10:02 PM
Biogen (BIIB) and Ionis Pharmaceuticals, Inc. (IONS) Announce Published ...Biogen (BIIB) and Ionis Pharmaceuticals, Inc. (IONS) Announce Published ...
www.streetinsider.com - February 16 at 8:31 AM
Ionis Pharmaceuticals to Hold 2017 Financial Results Conference Call - PR Newswire (press release)Ionis Pharmaceuticals to Hold 2017 Financial Results Conference Call - PR Newswire (press release)
www.prnewswire.com - February 15 at 8:04 AM
Biogen (BIIB) and Ionis Pharmaceuticals, Inc. (IONS) Announce Published SPINRAZA (nusinersen) Phase 3 Study ... - StreetInsider.comBiogen (BIIB) and Ionis Pharmaceuticals, Inc. (IONS) Announce Published SPINRAZA (nusinersen) Phase 3 Study ... - StreetInsider.com
www.streetinsider.com - February 15 at 8:04 AM
The New England Journal of Medicine Publishes SPINRAZA® (nusinersen) Phase 3 Study Results in Individuals with Later-Onset Spinal Muscular AtrophyThe New England Journal of Medicine Publishes SPINRAZA® (nusinersen) Phase 3 Study Results in Individuals with Later-Onset Spinal Muscular Atrophy
finance.yahoo.com - February 14 at 5:19 PM
Ionis Pharmaceuticals to Hold 2017 Financial Results Conference CallIonis Pharmaceuticals to Hold 2017 Financial Results Conference Call
finance.yahoo.com - February 13 at 9:50 AM
Financial Contrast: OncoSec Medical (ONCS) and Ionis Pharmaceuticals (IONS)Financial Contrast: OncoSec Medical (ONCS) and Ionis Pharmaceuticals (IONS)
www.americanbankingnews.com - February 12 at 3:16 PM
Ionis Pharmaceuticals (IONS) Downgraded to "Sell" at Zacks Investment ResearchIonis Pharmaceuticals (IONS) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - February 10 at 1:06 PM
Ionis Pharmaceuticals Inc (IONS) Receives Average Rating of "Hold" from BrokeragesIonis Pharmaceuticals Inc (IONS) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 9 at 12:53 PM
Ionis Pharmaceuticals Inc (IONS) Expected to Post Quarterly Sales of $115.44 MillionIonis Pharmaceuticals Inc (IONS) Expected to Post Quarterly Sales of $115.44 Million
www.americanbankingnews.com - February 8 at 9:04 AM
Zacks: Analysts Expect Ionis Pharmaceuticals Inc (IONS) Will Announce Earnings of -$0.08 Per ShareZacks: Analysts Expect Ionis Pharmaceuticals Inc (IONS) Will Announce Earnings of -$0.08 Per Share
www.americanbankingnews.com - February 6 at 1:12 AM
Ionis Pharmaceuticals Inc (IONS) SVP C Frank Bennett Sells 12,500 SharesIonis Pharmaceuticals Inc (IONS) SVP C Frank Bennett Sells 12,500 Shares
www.americanbankingnews.com - February 1 at 9:30 PM
Patrick R. Oneil Sells 355 Shares of Ionis Pharmaceuticals Inc (IONS) StockPatrick R. O'neil Sells 355 Shares of Ionis Pharmaceuticals Inc (IONS) Stock
www.americanbankingnews.com - January 31 at 6:56 PM
Insider Selling: Ionis Pharmaceuticals Inc (IONS) Director Sells 3,000 Shares of StockInsider Selling: Ionis Pharmaceuticals Inc (IONS) Director Sells 3,000 Shares of Stock
www.americanbankingnews.com - January 31 at 6:38 PM
Insider Selling: Ionis Pharmaceuticals Inc (IONS) Chairman Sells 11,000 Shares of StockInsider Selling: Ionis Pharmaceuticals Inc (IONS) Chairman Sells 11,000 Shares of Stock
www.americanbankingnews.com - January 31 at 6:24 PM
Ionis Pharmaceuticals Inc (IONS) SVP Sells $35,475.00 in StockIonis Pharmaceuticals Inc (IONS) SVP Sells $35,475.00 in Stock
www.americanbankingnews.com - January 29 at 6:50 PM
Traders Purchase High Volume of Put Options on Ionis Pharmaceuticals (IONS)Traders Purchase High Volume of Put Options on Ionis Pharmaceuticals (IONS)
www.americanbankingnews.com - January 28 at 2:34 AM
Notable Tuesday Option Activity: SWK, IONS, NYLD - NasdaqNotable Tuesday Option Activity: SWK, IONS, NYLD - Nasdaq
www.nasdaq.com - January 24 at 8:21 AM
Ionis Pharmaceuticals Is Poised To Disrupt Biotech - Seeking Alpha - Seeking AlphaIonis Pharmaceuticals Is Poised To Disrupt Biotech - Seeking Alpha - Seeking Alpha
seekingalpha.com - January 24 at 8:21 AM
Ionis Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for IONSIonis Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for IONS
www.nasdaq.com - January 23 at 5:14 PM
Ionis Pharmaceuticals Inc (IONS) Expected to Announce Earnings of -$0.06 Per ShareIonis Pharmaceuticals Inc (IONS) Expected to Announce Earnings of -$0.06 Per Share
www.americanbankingnews.com - January 20 at 5:24 AM
B Lynne Parshall Sells 5,986 Shares of Ionis Pharmaceuticals Inc (IONS) StockB Lynne Parshall Sells 5,986 Shares of Ionis Pharmaceuticals Inc (IONS) Stock
www.americanbankingnews.com - January 18 at 12:32 AM
Ionis Pharmaceuticals Inc (IONS) Chairman Sells $856,576.24 in StockIonis Pharmaceuticals Inc (IONS) Chairman Sells $856,576.24 in Stock
www.americanbankingnews.com - January 18 at 12:32 AM
Insider Selling: Ionis Pharmaceuticals Inc (IONS) COO Sells 2,821 Shares of StockInsider Selling: Ionis Pharmaceuticals Inc (IONS) COO Sells 2,821 Shares of Stock
www.americanbankingnews.com - January 18 at 12:32 AM
Insider Selling: Ionis Pharmaceuticals Inc (IONS) SVP Sells 2,696 Shares of StockInsider Selling: Ionis Pharmaceuticals Inc (IONS) SVP Sells 2,696 Shares of Stock
www.americanbankingnews.com - January 18 at 12:32 AM
Elizabeth L. Hougen Sells 2,724 Shares of Ionis Pharmaceuticals Inc (IONS) StockElizabeth L. Hougen Sells 2,724 Shares of Ionis Pharmaceuticals Inc (IONS) Stock
www.americanbankingnews.com - January 18 at 12:32 AM
Ionis Pharmaceuticals Inc (IONS) Insider Sarah Boyce Sells 2,196 SharesIonis Pharmaceuticals Inc (IONS) Insider Sarah Boyce Sells 2,196 Shares
www.americanbankingnews.com - January 18 at 12:32 AM
Will 2018 Be Ionis Pharmaceuticals, Inc.s Best Year Yet? - Nasdaq ... - NasdaqWill 2018 Be Ionis Pharmaceuticals, Inc.'s Best Year Yet? - Nasdaq ... - Nasdaq
www.nasdaq.com - January 15 at 3:34 PM
Ionis Pharmaceuticals Inc (IONS) Receives Consensus Recommendation of "Hold" from AnalystsIonis Pharmaceuticals Inc (IONS) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 15 at 12:06 PM
Comparing Ionis Pharmaceuticals (IONS) & OHR Pharmaceutical (OHRP)Comparing Ionis Pharmaceuticals (IONS) & OHR Pharmaceutical (OHRP)
www.americanbankingnews.com - January 15 at 7:12 AM
Ionis Pharmaceuticals Target of Unusually Large Options Trading (IONS)Ionis Pharmaceuticals Target of Unusually Large Options Trading (IONS)
www.americanbankingnews.com - January 14 at 3:38 AM
OncoGenex Pharmaceuticals (ACHV) and Ionis Pharmaceuticals (IONS) Critical ComparisonOncoGenex Pharmaceuticals (ACHV) and Ionis Pharmaceuticals (IONS) Critical Comparison
www.americanbankingnews.com - January 13 at 5:06 PM
IONS March 2nd Options Begin TradingIONS March 2nd Options Begin Trading
www.nasdaq.com - January 11 at 11:49 AM
Ionis Pharmaceuticals Inc (IONS) Chairman Sells $572,110.00 in StockIonis Pharmaceuticals Inc (IONS) Chairman Sells $572,110.00 in Stock
www.americanbankingnews.com - January 10 at 9:38 PM
This Is Why Alnylam Pharmaceuticals Soared 249% in 2017This Is Why Alnylam Pharmaceuticals Soared 249% in 2017
finance.yahoo.com - January 10 at 11:36 AM
Ionis Pharma (IONS) Says Inotersen NDA Accepted for Priority Review by FDA - StreetInsider.comIonis Pharma (IONS) Says Inotersen NDA Accepted for Priority Review by FDA - StreetInsider.com
www.streetinsider.com - January 8 at 3:38 PM
Implied Volatility Surging for Ionis Pharmaceuticals (IONS) Stock Options - NasdaqImplied Volatility Surging for Ionis Pharmaceuticals (IONS) Stock Options - Nasdaq
www.nasdaq.com - January 6 at 3:34 PM
Ionis Pharmaceuticals Inc (IONS) Chairman Sells $1,100,220.00 in StockIonis Pharmaceuticals Inc (IONS) Chairman Sells $1,100,220.00 in Stock
www.americanbankingnews.com - January 5 at 6:16 PM
Implied Volatility Surging for Ionis Pharmaceuticals (IONS) Stock OptionsImplied Volatility Surging for Ionis Pharmaceuticals (IONS) Stock Options
finance.yahoo.com - January 5 at 10:52 AM
-$0.06 EPS Expected for Ionis Pharmaceuticals Inc (IONS) This Quarter-$0.06 EPS Expected for Ionis Pharmaceuticals Inc (IONS) This Quarter
www.americanbankingnews.com - January 3 at 8:18 AM
Ionis Pharmaceuticals Inc (IONS) Director Joseph Klein III Sells 3,000 SharesIonis Pharmaceuticals Inc (IONS) Director Joseph Klein III Sells 3,000 Shares
www.americanbankingnews.com - January 2 at 7:32 PM
ETFs with exposure to Ionis Pharmaceuticals, Inc. : December 29, 2017ETFs with exposure to Ionis Pharmaceuticals, Inc. : December 29, 2017
finance.yahoo.com - December 29 at 3:33 PM
Ionis Pharmaceuticals, Inc. :IONS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 28, 2017Ionis Pharmaceuticals, Inc. :IONS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 28, 2017
finance.yahoo.com - December 28 at 10:22 AM
BidaskClub Lowers Ionis Pharmaceuticals (IONS) to HoldBidaskClub Lowers Ionis Pharmaceuticals (IONS) to Hold
www.americanbankingnews.com - December 22 at 7:32 PM
Ionis Pharma (IONS) Reports Initiation of Phase 1 Clinical Study of IONIS-JBI1-2.5Rx - StreetInsider.comIonis Pharma (IONS) Reports Initiation of Phase 1 Clinical Study of IONIS-JBI1-2.5Rx - StreetInsider.com
www.streetinsider.com - December 22 at 11:28 AM
Ionis Pharmaceuticals Inc (IONS) Given Consensus Rating of "Hold" by AnalystsIonis Pharmaceuticals Inc (IONS) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - December 21 at 11:50 AM
Ionis Pharmaceuticals Announces The Initiation Of A Clinical Study Of Its First Orally Delivered Antisense Drug For The Treatment Of Gastrointestinal DisordersIonis Pharmaceuticals Announces The Initiation Of A Clinical Study Of Its First Orally Delivered Antisense Drug For The Treatment Of Gastrointestinal Disorders
finance.yahoo.com - December 21 at 10:57 AM
Ionis Pharmaceuticals Inc (IONS) Director Sells $155,070.00 in StockIonis Pharmaceuticals Inc (IONS) Director Sells $155,070.00 in Stock
www.americanbankingnews.com - December 19 at 11:32 PM
Insider Selling: Ionis Pharmaceuticals Inc (IONS) SVP Sells 5,000 Shares of StockInsider Selling: Ionis Pharmaceuticals Inc (IONS) SVP Sells 5,000 Shares of Stock
www.americanbankingnews.com - December 19 at 11:32 PM
$115.44 Million in Sales Expected for Ionis Pharmaceuticals Inc (IONS) This Quarter$115.44 Million in Sales Expected for Ionis Pharmaceuticals Inc (IONS) This Quarter
www.americanbankingnews.com - December 19 at 5:54 AM

SEC Filings

Ionis Pharmaceuticals (NASDAQ:IONS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ionis Pharmaceuticals (NASDAQ:IONS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ionis Pharmaceuticals (NASDAQ IONS) Stock Chart for Sunday, February, 18, 2018

Loading chart…

This page was last updated on 2/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.